Haematological malignancies

828MO - Exonic mutation profile of primary gastrointestinal diffuse large B-cell lymphoma

Shan-Shan Li, et al. 


Our study provides a comprehensive view of the exonic mutational landscape of pGI-DLBCL, within which a specific gene cluster was mutated relating to humoral immunity activation and P2RY8 mutation was associated with patient prognosis.



829MO - A gene signature to predict risk of transformation in patients with follicular lymphoma

Ismael Fernandez-Miranda, et al.


In summary, genomic analysis on FL samples have enabled the association of mutated genes with higher risk of transformation. We have also demonstrated that mutations below 20% VAF in FL samples at diagnosis are associated with transformation. Integration of the mutational status with clinical risk factors into a predictive model improves the risk stratification and could be useful for identifying patients at higher risk of transformation.



830MO - Integrated driver mutations profile of Chinese NK/T cell lymphoma

Ting-zhi Liu, et al. 


In this study, the genome-wide analysis of 15 Chinese NK/T-cell lymphoma patients revealed that RETSAT, and SNRNP70 were the genes with the highest mutation frequencies. In addition, NK/T-cell lymphoma patients showed higher mutation frequencies in ARID1B, and ERBB3 oncogenes. These findings suggested the presence of possible driver genes, along with therapeutic targets for NKTCL. Furthermore, they illustrate characteristic mutation patterns, which are valuable for guiding future NKTCL research.



831MO - Geptanolimab in Chinese patients with relapsed or refractory primary mediastinal large B-cell lymphoma: Results from a multicenter, open-label, single-arm phase II trial

Yuan-Kai Shi, et al. 


Geptanolimab showed good anti-tumor activity with ORR of 64% and manageable safety profile in Chinese patients with relapsed or refractory PMBCL.



832MO - Immune microenvironment in classical Hodgkin lymphoma: Composition and dynamics in patients with relapsed/refractory disease

Liudmila Fedorova, et al.


We found that low number of CD163+ cells in primary samples were associated with inferior PFS during Nivo therapy, while a lower level of M2 was correlated with achievement of CR. In repeated biopsies after Nivo therapy the cell profile in the TME changed: number of PD-1+ and Lag-3+ T-cells increased and number of CD68+ and CD163+ macrophages decreased.